United Laboratories International Holdings Ltd
HKEX:3933
United Laboratories International Holdings Ltd
Operating Income
United Laboratories International Holdings Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Operating Income
¥3.5B
|
CAGR 3-Years
44%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Operating Income
HK$2.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
22%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Operating Income
¥6.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
14%
|
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
Operating Income
¥801.3m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
4%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Operating Income
HK$13B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Operating Income
-$120.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-77%
|
|
United Laboratories International Holdings Ltd
Glance View
United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.
See Also
What is United Laboratories International Holdings Ltd's Operating Income?
Operating Income
3.5B
CNY
Based on the financial report for Dec 31, 2024, United Laboratories International Holdings Ltd's Operating Income amounts to 3.5B CNY.
What is United Laboratories International Holdings Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
12%
Over the last year, the Operating Income growth was 5%. The average annual Operating Income growth rates for United Laboratories International Holdings Ltd have been 44% over the past three years , 26% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet